Physician

Jeffrey Louis Sugarman, M.D., PH.D.

According to 2025 Medicare claims, Jeffrey Sugarman, M.D., PH.D. (NPI: 1548255482) practices dermatology in the Santa Rosa-Petaluma, CA market, with the plurality of this provider's patient population coming from Sonoma, CA. This provider's primary affiliated billing organization is REDWOOD FAM DERMATOLOGY MEDICAL ASSOCIATES - A MEDICAL CORPORATION (NPI: 1710913231; TIN: 200489141) and primary practice location at 95403-2805.

Sugarman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 3,346 traditional Medicare patients, billed 13,815 HCPCS/CPT codes, and received $540,564 in Medicare payments. The top billing code was 11102 (Biopsy of related skin growth, first growth). Part D data shows 132 prescription claims across 53 beneficiaries totaling $183,843 in drug costs, led by Dupixent Pen (Dupilumab). Open Payments data shows 207 records totaling $104,534. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $891,930 and ending at $540,564. Concurrently, Part D prescription costs have risen steadily, from $44,883 to $183,843. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	4,960	20,324	$891,930
2016	3,983	12,038	$518,220
2017	3,589	10,370	$391,448
2018	2,968	11,725	$406,408
2019	3,461	15,351	$535,504
2020	2,981	13,040	$462,484
2021	3,244	16,511	$667,954
2022	3,620	17,069	$665,698
2023	3,374	14,128	$492,070
2024	3,346	13,815	$540,564

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	254	$44,883
2016	91	218	$78,343
2017	106	318	$128,141
2018	68	195	$107,131
2019	70	155	$13,263
2020	108	223	$210,500
2021	107	241	$172,826
2022	152	279	$303,298
2023	91	210	$164,607
2024	53	132	$183,843

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
11102	Biopsy of related skin growth, first growth	118	127	$70
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	173	220	$61
17000	Destruction of precancer skin growth, 1 growth	153	181	$41
88305	Pathology examination of tissue using a microscope, intermediate complexity	3,003	10,452	$32
88304	Pathology examination of tissue using a microscope, moderately low complexity	115	214	$20

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Pen	Dupilumab	11	308	$39,660
Fluocinonide	Fluocinonide	12	360	$452
Clobetasol Propionate	Clobetasol Propionate	15	420	$404
Hydrocortisone	Hydrocortisone	15	316	$99
Triamcinolone Acetonide	Triamcinolone Acetonide	19	477	$74

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	207	$104,534	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey Louis Sugarman, M.D., PH.D.?

Tedicare shows public-source Medicare data for Jeffrey Louis Sugarman, M.D., PH.D. (NPI 1548255482), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey Louis Sugarman, M.D., PH.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jeffrey Louis Sugarman, M.D., PH.D.?

Jeffrey Louis Sugarman, M.D., PH.D. is linked to REDWOOD FAM DERMATOLOGY MEDICAL ASSOCIATES - A MEDICAL CORPORATION (billing NPI 1710913231) in the available physician profile data.

Does Jeffrey Louis Sugarman, M.D., PH.D. have Open Payments data?

Jeffrey Louis Sugarman, M.D., PH.D. has 207 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.